Arcutis Q1 2026 revenue $105.4M (+65% YoY); net loss narrows to $11.3M

Arcutis Biotherapeutics, Inc.

2026-Q1 EPS reported -$0.09 revenue$105,398,000

Net product revenue of $105.4M from ZORYVE, up 65% YoY but down 17% sequentially due to Q1 seasonality.
Net loss of $11.3M ($0.09 per share) vs $25.1M loss in Q1 2025; positive operating cash flow of $2.2M.
FY 2026 revenue guidance maintained at $480M–$495M; cash and equivalents $224.3M at quarter end.
Submitted sNDA for ZORYVE cream 0.05% in atopic dermatitis for infants 3–24 months; initiated Phase 1 for ARQ-234.
Completed dermatology sales force expansion; hired head of Primary Care Franchise to target pediatric providers.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Arcutis Biotherapeutics, Inc. reported the quarter ended March 31, 2026 results: revenue $105.4 million.

Period: the quarter ended March 31, 2026
Revenue: $105.4 million
Result: reported results

Exact text from the filing

--- EX-99.1 (EX-99.1) --- Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update • Q1 2026 net product revenue for ZORYVE® (roflumilast) was $105.4 million, a 65% increase compared to Q1 2025, and a 17% decrease compared to Q4 2025 • Continued strong demand for ZORYVE despite typical Q1 seasonality, with continued growth in share of

View on SEC.gov

Browse all earnings releases →

Arcutis Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001787306-26-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.